Streetbeat News

Analyst Ratings

TREX

Trex Company, Inc. (NYSE:TREX) exceeded Q4 earnings and sales expectations, reporting adjusted earnings of 20 cents per share and quarterly sales of $195.75 million. The company forecasts FY24 net sales between $1.215 billion and $1.235 billion, significantly above estimates. Following the report, Trex shares dropped by 2.1%. Analysts from Truist Securities, Stifel, DA Davidson, and UBS have raised their price targets on Trex, maintaining Buy and Neutral ratings.

Portfolio Pulse from Avi Kapoor

February 27, 2024 | 6:19 pm

ALLO

JP Morgan analyst Brian Cheng maintains an Overweight rating on Allogene Therapeutics (NASDAQ:ALLO) but lowers the price target from $9 to $8.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 6:18 pm

WYNN

JP Morgan analyst Joseph Greff has maintained an Overweight rating on Wynn Resorts (NASDAQ:WYNN) and increased the price target from $118 to $123.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 6:16 pm

CI

Investors have shown a mixed sentiment towards Cigna Group (NYSE:CI), with options trading evenly split between bullish and bearish. Uncommon options activity has been detected, indicating potential insider knowledge of forthcoming developments. The options market is focusing on a price range of $280 to $310 for CI, based on recent trading volumes and open interest. Analysts have issued positive ratings for CI, with a consensus target price of $362.8, suggesting optimism about the company's future performance.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 6:15 pm

TMDX

JP Morgan analyst Allen Gong maintains an Overweight rating on TransMedics Group (TMDX) and raises the price target from $87 to $105.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 6:13 pm

MELI

JP Morgan analyst Marcelo Santos has maintained an Overweight rating on MercadoLibre (NASDAQ:MELI) and increased the price target from $2000 to $2150.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 6:10 pm

HIMS

Hims & Hers Health, Inc. (NYSE:HIMS) reported better-than-expected Q4 earnings, beating analyst estimates with earnings of 1 cent per share and quarterly sales of $246.62 million. The company also issued strong guidance for Q1 2024 and FY 2024, expecting to surpass $1 billion in revenue. Following the report, HIMS shares surged 31.9% to $13.52. Analysts from Truist Securities, Piper Sandler, Citigroup, and Guggenheim have subsequently raised their price targets on HIMS.

Portfolio Pulse from Avi Kapoor

February 27, 2024 | 6:10 pm

FRPT

JP Morgan analyst Ken Goldman has maintained a Neutral rating on Freshpet (NASDAQ:FRPT) and increased the price target from $67 to $102.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 6:08 pm

ALB

Albemarle's stock price increased following Mizuho's decision to maintain a Neutral rating while raising its price target from $105 to $115.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 6:07 pm

FIS

JP Morgan analyst Tien-Tsin Huang maintains an Overweight rating on Fidelity National Info (FIS) and raises the price target from $71 to $75.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 6:06 pm